Patent cliffs & loss of exclusivity
Mirum Pharmaceuticals develops and commercializes medicines for rare diseases, including rare liver and genetic disorders. Its approved portfolio includes LIVMARLI, CHOLBAM, CTEXLI and ATEBRIOZ, alongside investigational programs for cholestatic liver diseases, hepatitis delta and Fragile X syndrome. Founded in 2018, the company is headquartered in Foster City, California.
| Legal Name | Mirum Pharmaceuticals, Inc. |
|---|---|
| Company Operating Status | Active |
| Crunchbase URL | https://www.crunchbase.com/organization/mirum-pharmaceuticals |
| Email format | {f}{last} |
| Facebook URL | https://www.facebook.com/mirumpharma/ |
| Full Address | 950 Tower Lane, Suite 1050, Foster City, CA 94404, US |
| Instagram URL | https://www.instagram.com/mirumpharma/ |
| LinkedIn URL | https://www.linkedin.com/company/mirum-pharmaceuticals |
Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.